What drove the significant improvement in net income for the quarter?

The significant improvement in net income was driven by a combination of factors. Firstly, the company's core operations showed recovery, particularly in cardiac surgery and critical care product sales. Secondly, the adoption of SFAS No. 142 eliminated goodwill amortization, which had a positive impact on reported earnings. Lastly, a one-time $20 million cash payment received from a legal settlement with Medtronic significantly boosted "Other (Income) Expense, net."

Why did net sales decrease year-over-year?

The decrease in net sales for the quarter was primarily due to the sale of the company's perfusion services business in the United States, which occurred on June 30, 2001. Excluding this divestiture, net sales in the United States would have shown growth.

What is the status of the legal proceedings mentioned in the filing?

Edwards Lifesciences has settled its patent infringement lawsuits with Medtronic, Inc., receiving a $20 million cash payment and granting a royalty-bearing license. However, the company is still involved in a patent infringement lawsuit against St. Jude Medical, Inc. Management believes that the resolution of pending legal matters will not have a material adverse effect on the company's consolidated financial position, although charges in excess of reserves could impact net income or cash flows in the period they are recorded or paid.

How has the adoption of SFAS No. 142 impacted the financial statements?

The adoption of SFAS No. 142, effective January 1, 2002, changed the accounting for goodwill from an amortization method to an impairment-only approach. This resulted in the elimination of goodwill amortization for the current periods, positively impacting reported operating income and net income compared to prior periods where goodwill amortization was a significant expense.

EW 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported a significant turnaround in financial performance for the quarter ending June 30, 2002, compared to the same period in the prior year. The company achieved a net income of $30.6 million, a substantial improvement from a net loss of $55.7 million in Q2 2001. This was driven by a recovery in net sales, particularly in the cardiac surgery and critical care segments, with total net sales reaching $172.8 million, down 10.2% year-over-year, largely due to the sale of the US perfusion services business. The improved profitability is also attributed to the adoption of SFAS No. 142, which eliminated goodwill amortization, and a $20 million legal settlement received from Medtronic, which contributed to a significant positive swing in "Other (Income) Expense, net." The company's balance sheet shows total assets of $983.3 million and total stockholders' equity of $479.6 million as of June 30, 2002. Investors should note the ongoing legal proceedings with St. Jude Medical, Inc. and the planned acquisition of the Japanese business from Baxter, expected to close October 1, 2002.

Key Highlights

1Net income turned positive, reaching $30.6 million for the quarter ended June 30, 2002, a significant improvement from a net loss of $55.7 million in the prior year period.
2Total net sales for the quarter were $172.8 million, a decrease of 10.2% year-over-year, primarily due to the divestiture of the US perfusion services business.
3Cardiac Surgery and Critical Care segments showed strong sales growth, up 9.0% and 2.4% respectively on an adjusted basis for the quarter.
4The company recorded a $14.7 million net gain from a legal settlement with Medtronic, contributing to improved "Other (Income) Expense, net."
5Adoption of SFAS No. 142 eliminated goodwill amortization starting January 1, 2002, positively impacting operating income.
6Total cash and cash equivalents decreased to $35.5 million from $47.7 million at the beginning of the year, with net cash used in financing activities driven by long-term debt payments and stock repurchases.
7The company is planning to acquire its Japanese business from Baxter, expected to close on October 1, 2002.

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions